Literature DB >> 18329742

Potential improvement of tumor control probability by induction chemotherapy for advanced nasopharyngeal carcinoma.

Anne W M Lee1, Kam Ying Lau, Wai Man Hung, Wai Tong Ng, Michael C H Lee, Cheuk Wai Choi, Connie C C Chan, Raymond Tung, Peter T C Cheng, Tsz Kok Yau.   

Abstract

PURPOSE: To assess the reduction of tumor bulk and improvement of tumor control probability (TCP) by using induction chemotherapy for advanced nasopharyngeal carcinoma (NPC).
MATERIALS AND METHODS: From February to December 2005, 20 patients with Stage III-IVB NPC were treated with induction-concurrent chemotherapy and intensity-modulated radiotherapy with accelerated fractionation. Combination of cisplatin and 5-fluorouracil was used in the induction phase and single agent Cisplatin in the concurrent phase. All patients were irradiated at 2Gy per fraction, 6 daily fractions per week, to a total dose of 70Gy.
RESULTS: Nineteen (95%) patients completed all 3 cycles of induction chemotherapy and 90% had 2 cycles of concurrent chemotherapy. Induction chemotherapy achieved significant down-staging of T-category in 35% of patients (p=0.016) and reduction of gross tumor volume (GTV_P) from 55.6 to 22.9cc (mean 61.4%, p<0.001). Although the mean radiation dose did not show any substantial change, the volume within GTV_P that failed to reach 70Gy was reduced from 10.2% to 3.8% (p=0.017). The estimated local TCP increased from 0.83 to 0.89 (p=0.002).
CONCLUSIONS: Induction chemotherapy using cisplatin-5-fluorouracil could significantly reduce tumor bulk leading to potential improvement in tumor control.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18329742     DOI: 10.1016/j.radonc.2008.02.003

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  28 in total

1.  Magnetic Resonance Imaging Volumetry of Primary Nasopharyngeal Cancer in Patients Treated with Induction Gemcitabine and Cisplatin Followed by Concurrent Cisplatin and Volumetric Modulated Arc Therapy.

Authors:  Joshua Giambattista; Nevin McVicar; Sarah Hamilton; Montgomery Martin; Benjamin Maas; Cheryl Ho; Jonn Wu; Eric Tran; John Hay; Eric Berthelet
Journal:  Cureus       Date:  2018-09-13

2.  Hypofractionated radiotherapy with simultaneous integrated boost (SIB) plus temozolomide in good prognosis patients with glioblastoma: a multicenter phase II study by the Brain Study Group of the Italian Association of Radiation Oncology (AIRO).

Authors:  Silvia Scoccianti; Marco Krengli; Livia Marrazzo; Stefano Maria Magrini; Beatrice Detti; Vincenzo Fusco; Luigi Pirtoli; Daniela Doino; Alba Fiorentino; Laura Masini; Daniela Greto; Michela Buglione; Giovanni Rubino; Federico Lonardi; Fernanda Migliaccio; Salvino Marzano; Riccardo Santoni; Umberto Ricardi; Lorenzo Livi
Journal:  Radiol Med       Date:  2017-09-06       Impact factor: 3.469

3.  Predicting the dose absorbed by organs at risk during intensity modulated radiation therapy for nasopharyngeal carcinoma.

Authors:  Haowen Pang; Xiaoyang Sun; Bo Yang; Jingbo Wu
Journal:  Br J Radiol       Date:  2018-08-10       Impact factor: 3.039

4.  Factors associated with nodal metastasis in nasopharyngeal cancer: an approach to reduce the radiation field in selected patients.

Authors:  Natsuo Tomita; N Fuwa; Y Ariji; T Kodaira; N Mizoguchi
Journal:  Br J Radiol       Date:  2010-10-19       Impact factor: 3.039

5.  Conventional 2D (2DRT) and 3D conformal radiotherapy (3DCRT) versus intensity-modulated radiotherapy (IMRT) for nasopharyngeal cancer treatment.

Authors:  Francesco Moretto; Monica Rampino; Fernando Munoz; Maria Grazia Ruo Redda; Alessia Reali; Vittoria Balcet; Serena Badellino; Cristina Piva; Marina Schena; Mario Airoldi; Oliviero Ostellino; Giancarlo Pecorari; Riccardo Ragona; Umberto Ricardi
Journal:  Radiol Med       Date:  2014-01-15       Impact factor: 3.469

Review 6.  Nasopharyngeal carcinoma: an evolving paradigm.

Authors:  Kenneth C W Wong; Edwin P Hui; Kwok-Wai Lo; Wai Kei Jacky Lam; David Johnson; Lili Li; Qian Tao; Kwan Chee Allen Chan; Ka-Fai To; Ann D King; Brigette B Y Ma; Anthony T C Chan
Journal:  Nat Rev Clin Oncol       Date:  2021-06-30       Impact factor: 66.675

7.  Radiation-induced gray matter atrophy in patients with nasopharyngeal carcinoma after intensity modulated radiotherapy: a MRI magnetic resonance imaging voxel-based morphometry study.

Authors:  Lei Shi; Feng-Lei Du; Zong-Wen Sun; Lan Zhang; Yuan-Yuan Chen; Tie-Ming Xie; Pei-Jing Li; Shuang Huang; Bai-Qiang Dong; Min-Ming Zhang
Journal:  Quant Imaging Med Surg       Date:  2018-10

8.  Intensity modulated radiotherapy (IMRT) combined with concurrent but not adjuvant chemotherapy in primary nasopharyngeal cancer - a retrospective single center analysis.

Authors:  Ladan Saleh-Ebrahimi; Felix Zwicker; Marc W Muenter; Marc Bischof; Katja Lindel; Juergen Debus; Peter E Huber; Falk Roeder
Journal:  Radiat Oncol       Date:  2013-01-24       Impact factor: 3.481

Review 9.  Emerging treatment options for nasopharyngeal carcinoma.

Authors:  Lu Zhang; Qiu-Yan Chen; Huai Liu; Lin-Quan Tang; Hai-Qiang Mai
Journal:  Drug Des Devel Ther       Date:  2013-02-01       Impact factor: 4.162

10.  Using neoadjuvant chemotherapy and replanning intensity-modulated radiotherapy for nasopharyngeal carcinoma with intracranial invasion to protect critical normal tissue.

Authors:  Xiaoshuang Niu; Xi Chang; Yunsheng Gao; Chaosu Hu; Lin Kong
Journal:  Radiat Oncol       Date:  2013-10-02       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.